Assessment of Radiotherapy-Associated Angiosarcoma After Breast Cancer Treatment in a Dutch Population-Based Study
Radiotherapy-associated angiosarcoma (RAAS) has been reported as a rare, but serious late complication of radiotherapy (RT) for breast cancer. 1, 2 This study describes the incidence, latency period, and outcomes of RAAS using the prospective database from the nationwide Netherlands Cancer Registry. ) was used to determine the incidence and predictive factors of RAAS. Survival after treatment of RAAS was analyzed using Kaplan-Meier curves. The Cox proportional hazards regression model was used for multivariable analysis. Follow-up was defined as the time from incidence of RAAS until the date of death or the last date of follow-up. Statistical significance was defined as 2-sided P < .05. Data were analyzed from January 1, 1989, through January 1, 2017. Following good clinical practice rules in the Netherlands, one does not need to ask ethical approval for the use of anonymized cohort data.
Methods
Results | Among the population of 296 577 patients included in the analysis (median age at diagnosis, 58 years [range, 18-97 years]), median follow-up after diagnosis of breast cancer was 7.7 years (range, 0-28.1 years). Of the patients who did not receive RT (n = 111 754), none developed an angiosarcoma. Of the 184 823 patients who received RT, 209 (0.1% [1 of 1000]) developed RAAS of the breast and/or chest wall (Table) . Older patients with breast cancer were at increased risk for the development of RAAS (hazard ratio [HR], 1.05; 95% CI, 1.04-1.06). Patients who underwent a mastectomy for the primary tumor were less likely to develop RAAS compared with patients who underwent breast-conserving therapy (HR, 0.22; 95% CI, 0.10-0.49).
The median latency period from breast cancer treatment to development of RAAS was 8 years (range, 3-20 years) (Figure) . Data on RAAS treatment were available in 194 patients (92.8%). Most patients underwent surgery only (166 [79.4%]). Nineteen patients (9.1%) underwent a combination of surgery and RT (9.1%), which was combined with hyperthermia therapy in 13. Three patients (1.4%) underwent a combination of surgery and chemotherapy and 6 (2.9%) underwent chemotherapy or RT only.
Regardless of the treatment given for RAAS, 5-and 10-year overall survival rates were 40.5% (95% CI, 33.1%-47.9%) and 25.2% (95% CI, 17.4%-33.0%), respectively. Compared with surgery alone, the addition of RT to the treatment of RAAS did not significantly improve survival during univariable or multivariable analysis (HR, 0.61; 95% CI, 0.28-1.34).
Discussion | The present study provides the largest original series of RAAS to date (n = 209), to our knowledge. The cumulative incidence of RAAS in 1 per 1000 patients with breast cancer who underwent RT is comparable with numbers as reported in the literature in smaller series of 0.9 to 1.1 per 1000 patients. 4, 5 Importantly, angiosarcomas did not occur in any of the patients who did not receive RT.
Overall 5-year survival in patients with RAAS was 40.5% without significant differences in treatment modalities.
A recent review by Depla et al 1 included all literature in the English language on RAAS from 1985 to 2013 and described 222 patients from case reports and small series. The investigators suggested that surgery in combination with RT might improve local control. 1 Another study 6 suggested a beneficial effect of hyperthermia therapy in combination with RT. None of the studies showed an association with overall survival. In the Netherlands Cancer Registry database, data on local recurrences is lacking, but similarly to previous studies, no statistically significant survival benefit was found in patients who underwent surgery and RT compared with patients who underwent surgery alone. However, the number of patients treated with surgery and RT was low in the present study. Our data show that treatment of RAAS should include surgery. A beneficial effect on overall survival of the addition of RT to the treatment of RAAS could not be confirmed in this population-based analysis, and evidence in the literature also lacks power to draw firm conclusions. This study demonstrates that the low incidence of RAAS renders a prospective analysis practically not feasible. Entering the outcomes of RAAS into a prospective international database could be considered. Includes 209 patients with breast cancer and treated with radiotherapy ascertained from the Netherlands Cancer Registry.
Letters
In Reply We thank Dr Zhang and colleagues for their comment regarding the grading of adverse events in the phase 3 PETACC-3 trial, which compared biweekly infusional fluorouracil/leucovorin alone or in combination with irinotecan as adjuvant treatment of stage 3 colon cancer. 1 We agree with Dr Zhang that the quality of adverse event grading is a critical issue in clinical trials, especially when evaluating factors influencing toxic effects. However, in contrast to what Zhang and colleagues assume, the investigators of the PETACC-3 trial 1 graded alopecia correctly as mentioned in our article 2 ; adverse events were graded according to the National Cancer Institute of Canada Common Toxicity Grading expanded common toxicity criteria (version revised in May 1991, which was detailed in the PETACC-3 protocol but is no longer available for reference). In this version, alopecia is graded from grade 1 (mild hair loss) to grade 3 (total body hair loss). Therefore, no correction is needed; in 2974 patients receiving chemotherapy, 1.4% of women vs 0.4% of men presented with an alopecia grade greater than 2. 2 It is in the Common Toxicity Criteria version 2.0 and later that alopecia was graded as either grade 1 (mild hair loss) or grade 2 (pronounced hair loss). 3 Moreover, we would like to mention that, regardless of the number of categories in which alopecia is graded, a bias in the comparative assessment of the severity of alopecia between men and women is likely to be introduced by differences in baseline condition, with men more often having alopecia at baseline. Furthermore, sex differences in the subjective perception of the
